TScan Therapeutics (TCRX) Capital Expenditures (2020 - 2026)

TScan Therapeutics (TCRX) has reported Capital Expenditures for 7 consecutive years, with $70000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 95.43% year-over-year to $70000.0; the TTM figure through Mar 2026 stood at -$1.5 million (down 131.28% YoY), while the FY2025 annual figure was $7000.0, down 99.82% from the prior year.
• Capital Expenditures advanced to $70000.0 in Q1 2026 per TCRX's latest filing, from -$45000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.9 million in Q2 2022 and bottomed at -$1.9 million in Q3 2022.
• Historically, Capital Expenditures has averaged $273352.9 across 5 years, with a median of $70000.0 in 2026.
• Annual changes were most pronounced in 2024 — Capital Expenditures soared 2837.5% — and 2025, when it tumbled 170.07%.
• TScan Therapeutics' Capital Expenditures stood at -$128000.0 in 2022, then soared by 67.19% to -$42000.0 in 2023, then jumped by 2214.29% to $888000.0 in 2024, then slumped by 105.07% to -$45000.0 in 2025, then soared by 255.56% to $70000.0 in 2026.
• Business Quant data shows TCRX's Capital Expenditures at $70000.0 in Q1 2026, -$45000.0 in Q4 2025, and -$876000.0 in Q3 2025.